

Generation of the lead antibody targeting APP, a novel immuno-oncology target

Genome & Company
GENOME & CO

ONCOLOGY	Lead
Product Type	Biologics, humanized monoclonal antibody with hIgG4 (S228P) isotype
Indication	Solid tumor
Target	APP (Amyloid Precursor Protein)
MoA (Mechanism of Action)	Targeting APP, a novel immune checkpoint expressed in T cells, obstructs communication between T cells and cancer cells expressing CNTN4 (Contactin 4), helping restore T cell activity and responsiveness to tumors.
Competitiveness	APP's binding partner, CNTN4, is expressed highly in non-responders of anti-PD-1 therapy, and it is overexpressed in various solid tumors, specifically the tumors of the bladder, prostate, liver, endometrium, liver, stomach, pancreas, gallbladder, and melanoma, with the inverse trend with PD-L1 expression. Targeting APP as the first-in-class approach will be a new opportunity for cancer patients who do not benefit from targeting PD-1 or PD-L1.
Development Stage	Lead
Route of Administration	Intravenous injection